SK Biopharmaceuticals, a South Korean biotechnology firm, has announced the formation of a joint venture with Brazilian pharmaceutical company Eurofarma to create an advanced platform for managing epilepsy through artificial intelligence. The new entity, named Mentis Care, aims to revolutionize epilepsy care by commercializing an AI-based management system.
The announcement was made during a launch event on October 20, 2025, in Toronto, Canada, marking a significant step for SK Biopharmaceuticals as it expands its digital healthcare initiatives beyond its traditional focus on drug development.
Since 2018, SK Biopharmaceuticals has developed its capabilities in AI-enhanced electroencephalography (EEG) and wearable technologies for real-time seizure detection and monitoring. Mentis Care plans to utilize these technologies to create a comprehensive platform that integrates real-time seizure prediction algorithms with clinical decision support tools, facilitating personalized care for patients.
Situated in the MaRS Discovery District, one of North America”s major innovation hubs, Mentis Care intends to build a local team, foster partnerships with academic and industry players, and validate its AI algorithms through clinical trials. Eurofarma will lead the business strategy and AI data learning aspects of the venture, building on their collaboration with SK Biopharmaceuticals that began in 2022 with the development of the anti-seizure medication cenobamate, marketed as XCOPRI in the U.S.
Taking the helm as Chief Executive Officer of Mentis Care is Hassan Kotob, a seasoned executive in healthcare technology. He aims to spearhead the development of this innovative platform, which is designed to transform how seizures and other neurological events are forecasted and managed.
“Mentis Care is an AI-driven digital health company with the mission to help patients with epilepsy live safer and more independently through AI-powered seizure prediction and monitoring,” Kotob stated. He emphasized the goal of setting a new standard in digital epilepsy management for patients globally.
Rodrigo Pereira, Global Executive Director of Entrepreneurship and Digital at Eurofarma, expressed enthusiasm for the joint venture, stating, “For Eurofarma, the JV represents the future we envision for healthcare, combining digital technologies and medicines for a transformative and positive leap in patients” lives.”
Donghoon Lee, Chief Executive Officer of SK Biopharmaceuticals, added that the venture marks a shift into digital healthcare, indicating the company”s commitment to patient-centered innovation through the integration of AI and clinical data.
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals, is based in Paramus, New Jersey, and focuses on developing treatments for central nervous system disorders and oncology. The SK Group, to which SK Biopharmaceuticals belongs, is one of South Korea”s largest conglomerates, known for its investments in various industries including biopharmaceuticals and digital business.
Eurofarma, founded in 1972, operates in various pharmaceutical segments and is recognized as a leader in medical prescriptions in Brazil. The company is also notable for its extensive portfolio and commitment to improving healthcare quality across Latin America and beyond.
Mentis Care aims to set a new benchmark in the management of epilepsy through its predictive AI technology, providing enhanced safety and peace of mind for patients and their families.
